Investments
53Portfolio Exits
21About North Sound Capital
North Sound Capital LLC is an employee owned hedge fund sponsor. The firm provides its services to pooled investment vehicles. It invests in the public equity markets of the United States. The firm was formerly known as DMG Advisors, LLC. North Sound Capital is based in Greenwich, Connecticut with an additional office in Denver, Colorado.

Want to inform investors similar to North Sound Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest North Sound Capital News
May 14, 2019
IsoPlexis , a Branford, Conn.-based company focused on advancing single-cell biomarkers to address critical challenges in oncology & beyond, raised $25m in Series C funding. The round was led by Northpond Ventures with participation from current investors Spring Mountain Capital, Ironwood Capital, North Sound Capital, and Connecticut Innovations. Led by Sean Mackay, CEO and co-founder, IsoPlexis aims to accelerate the fight against cancer and a range of the world’s toughest diseases with its single-cell detection systems. By revealing unique immune biomarkers in small subsets of cells, the company is advancing immunotherapies and targeted therapies to a more precise & personalized stage. Its integrated systems are used globally to advance the field of single-cell biology and biomarkers. In 2018, IsoPlexis’ novel single-cell immune biomarkers accelerated insights in the field of cancer immunotherapy. Its single-cell polyfunctional strength product predicted responses of CAR engineered T cell therapy patients in blood cancers, pre-therapy, for the first time. Customers also released multiple data sets defining the quality of patient response of CAR-T, TCR-T, CRISPR edited T-cells, and more. Additionally, its systems achieved correlative data through its novel profiling of TILs and T-cell from the blood of checkpoint immunotherapy patients. IsoPlexis rapidly expanded its user base with the launch of the IsoLight system at various Cancer Centers and biopharmas in the US, Europe and China in the second half of 2018. For 2019, the company has begun to share information on new single-cell product launches to address high need areas based on data generated and published on IsoPlexis’ platform. These include: single-cell polyfunctional inflammation solutions targeted towards neuroinflammation and autoimmunity, single-cell solutions for innate & myeloid cell types that contribute to immunotherapy response, single-cell energy state assays focused on advanced metabolomics in oncology, and tumor resistance assays focused on advanced tumor signaling. In continuing its path forward, the company continues to utilize its internal application engine and its partnerships with university professors and co-founders to build innovative single-cell products addressing high need disease areas. Additionally, it will expand its global operational, manufacturing, and commercial team across US, Europe and Asia, to add to the 105 employees IsoPlexis has currently. FinSMEs
North Sound Capital Investments
53 Investments
North Sound Capital has made 53 investments. Their latest investment was in Iridia as part of their Series A - V on March 3, 2021.

North Sound Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
3/16/2021 | Series A - V | Iridia | $6M | Yes | 1 | |
11/14/2018 | Series C | IsoPlexis | $25M | Yes | 4 | |
4/5/2007 | Series B | Sirion Holdings | $45M | Yes | ||
9/22/2006 | Private Equity - III | |||||
6/9/2006 | Unattributed VC - III |
Date | 3/16/2021 | 11/14/2018 | 4/5/2007 | 9/22/2006 | 6/9/2006 |
---|---|---|---|---|---|
Round | Series A - V | Series C | Series B | Private Equity - III | Unattributed VC - III |
Company | Iridia | IsoPlexis | Sirion Holdings | ||
Amount | $6M | $25M | $45M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 4 |
North Sound Capital Portfolio Exits
21 Portfolio Exits
North Sound Capital has 21 portfolio exits. Their latest portfolio exit was Antares Pharma on May 24, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
5/24/2022 | Acq - P2P | 5 | |||
10/8/2021 | IPO | Public | 6 | ||
6/21/2012 | Acquired | ||||
Date | 5/24/2022 | 10/8/2021 | 6/21/2012 | ||
---|---|---|---|---|---|
Exit | Acq - P2P | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 5 | 6 |
North Sound Capital Acquisitions
1 Acquisition
North Sound Capital acquired 1 company. Their latest acquisition was FiberNet Telecom Group on January 24, 2003.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
1/24/2003 | Private Equity | $57.58M | Acquired |
Date | 1/24/2003 |
---|---|
Investment Stage | Private Equity |
Companies | |
Valuation | |
Total Funding | $57.58M |
Note | Acquired |
Sources |
North Sound Capital Team
1 Team Member
North Sound Capital has 1 team member, including former Managing Director, Sandeep Steve Laumas.
Name | Work History | Title | Status |
---|---|---|---|
Sandeep Steve Laumas | BAM Elevate, and Goldman Sachs | Managing Director | Former |
Name | Sandeep Steve Laumas |
---|---|
Work History | BAM Elevate, and Goldman Sachs |
Title | Managing Director |
Status | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.